An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse.

Trial Profile

An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder; Drug abuse
  • Focus Therapeutic Use
  • Acronyms PEACE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Aug 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Actual end date (1 Jul 2009) added as reported by ClinicalTrials.gov.
    • 13 Jan 2010 Actual patient number (7) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top